JP2008512490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512490A5 JP2008512490A5 JP2007531414A JP2007531414A JP2008512490A5 JP 2008512490 A5 JP2008512490 A5 JP 2008512490A5 JP 2007531414 A JP2007531414 A JP 2007531414A JP 2007531414 A JP2007531414 A JP 2007531414A JP 2008512490 A5 JP2008512490 A5 JP 2008512490A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- agent
- pharmaceutical composition
- independently
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229940119059 actemra Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60788304P | 2004-09-08 | 2004-09-08 | |
| US61148204P | 2004-09-20 | 2004-09-20 | |
| PCT/US2005/032352 WO2006029385A2 (en) | 2004-09-08 | 2005-09-08 | Quinazoline derivatives as metabolically inert antifolate compounds. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512490A JP2008512490A (ja) | 2008-04-24 |
| JP2008512490A5 true JP2008512490A5 (OSRAM) | 2008-10-30 |
Family
ID=36037042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531414A Pending JP2008512490A (ja) | 2004-09-08 | 2005-09-08 | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7829708B2 (OSRAM) |
| EP (1) | EP1791544A4 (OSRAM) |
| JP (1) | JP2008512490A (OSRAM) |
| AU (1) | AU2005282241B2 (OSRAM) |
| CA (1) | CA2579096C (OSRAM) |
| WO (1) | WO2006029385A2 (OSRAM) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| KR101119448B1 (ko) | 2002-09-11 | 2012-03-15 | 추가이 세이야쿠 가부시키가이샤 | 단백질 정제 방법 |
| US8028438B2 (en) * | 2004-07-02 | 2011-10-04 | Aqualizer, Llc | Moisture condensation control system |
| EP1791544A4 (en) * | 2004-09-08 | 2007-09-12 | Chelsea Therapeutics Inc | CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE |
| US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| ES2524015T3 (es) * | 2005-12-30 | 2014-12-03 | Dyax Corporation | Proteínas de enlazamiento a la metaloproteinasa |
| EP1993384A2 (en) * | 2006-01-11 | 2008-11-26 | Attune Foods | Probiotic food, process for its preparation and dietary regimen |
| EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
| AU2007204410A1 (en) * | 2006-01-12 | 2007-07-19 | Novartis Ag | Combination of mTOR inhibitor and antipolate compound |
| GB0608821D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | DHFR enzyme inhibitors |
| WO2007147265A1 (en) | 2006-06-23 | 2007-12-27 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| US7820689B2 (en) * | 2006-08-10 | 2010-10-26 | Hua-Lin Wu | Methods and compositions for preventing or treating cardiovascular disease |
| WO2008052145A2 (en) | 2006-10-25 | 2008-05-02 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| WO2008052143A2 (en) | 2006-10-25 | 2008-05-02 | Revalesio Corporation | Mixing device and output fluids of same |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| CN101652366A (zh) * | 2007-01-19 | 2010-02-17 | 切尔西治疗公司 | 新型抗叶酸剂 |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US20090227018A1 (en) * | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| WO2009079585A2 (en) | 2007-12-17 | 2009-06-25 | Dyax Corp. | Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins |
| EP2282740A1 (en) * | 2008-04-07 | 2011-02-16 | Chelsea Therapeutics, Inc. | Antifolate compositions |
| WO2009134929A2 (en) | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| AU2009308369A1 (en) * | 2008-10-22 | 2010-04-29 | Dyax Corp. | Combination treatments comprising protease binding proteins for inflammatory disorders |
| CA3050455A1 (en) | 2008-11-03 | 2010-06-03 | Adc Therapeutics Sa | Antibodies that specifically block the biological activity of a tumor antigen |
| US20100260825A1 (en) * | 2009-04-13 | 2010-10-14 | Nair Madhavan G | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| WO2011005832A1 (en) * | 2009-07-08 | 2011-01-13 | Chelsea Therapeutics, Inc. | Stable crystalline polymorphs of the dipotassium salt of (s) -2- {4- [2- (2, 4-diamin0-quinaz0lin-6-yl) -ethyl] -benzoylamino} -4-methylenξ-penta nedioic acid |
| US9364507B2 (en) | 2009-08-11 | 2016-06-14 | Imagilin Technology, Llc | Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases |
| US9289469B2 (en) * | 2009-09-10 | 2016-03-22 | Mayo Foundation For Medical Education And Research | Depleting immunosuppressive monocytes within a mammal |
| WO2011056957A2 (en) * | 2009-11-06 | 2011-05-12 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
| NZ600208A (en) * | 2009-11-17 | 2014-06-27 | Cipla Ltd | Inhalation solutions |
| ES2388478T3 (es) * | 2009-12-02 | 2012-10-15 | Bettina Heil | Supositorio para la administración rectal, vaginal o uretral que contiene un probiótico, un antibiótico y un ácido graso insaturado no esterificado |
| US8471041B2 (en) * | 2010-02-09 | 2013-06-25 | Alliant Techsystems Inc. | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
| WO2012064377A1 (en) * | 2010-03-29 | 2012-05-18 | Chelsea Therapeutics, Inc. | Antifolate compositions |
| US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| CN103347500A (zh) | 2010-08-12 | 2013-10-09 | 利发利希奥公司 | 用于治疗tau蛋白病的组合物和方法 |
| WO2012078708A1 (en) | 2010-12-07 | 2012-06-14 | Chelsea Therapeutics, Inc. | Combination comprising methotrexate and an antifolate compound |
| WO2012078992A1 (en) * | 2010-12-09 | 2012-06-14 | Radiorx, Inc. | Organonitro compounds for use in treating non-hodgkin's lymphoma and leukemia, and methods relating thereto |
| SI3173427T1 (sl) | 2011-03-31 | 2019-08-30 | ADC Therapeutics SA, | Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega |
| US8664247B2 (en) | 2011-08-26 | 2014-03-04 | Radiorx, Inc. | Acyclic organonitro compounds for use in treating cancer |
| US9139519B2 (en) | 2011-10-07 | 2015-09-22 | Epicentrx, Inc. | Organonitro thioether compounds and medical uses thereof |
| WO2013052803A2 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| WO2013059439A2 (en) | 2011-10-21 | 2013-04-25 | Dyax Corp. | Combination therapy comprising an mmp-14 binding protein |
| SG10201701004RA (en) | 2012-01-06 | 2017-04-27 | Omthera Pharmaceuticals Inc | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
| IN2014CN04690A (OSRAM) | 2012-01-09 | 2015-09-18 | Alethia Biotherapeutics Inc | |
| EP2883108B1 (en) | 2012-08-08 | 2022-06-22 | Kinestral Technologies, Inc. | Electrochromic multi-layer devices with composite electrically conductive layers |
| US9507233B2 (en) | 2012-08-08 | 2016-11-29 | Kinestral Technologies, Inc. | Electrochromic multi-layer devices with current modulating structure |
| WO2014025913A1 (en) | 2012-08-08 | 2014-02-13 | Kinestral Technologies, Inc. | Electrochromic multi-layer devices with composite current modulating structure |
| BR112016017112A2 (pt) | 2014-01-24 | 2017-08-08 | Ai Therapeutics Inc | Composições de apilimod e métodos de uso das mesmas |
| PT3215157T (pt) | 2014-11-07 | 2019-07-12 | Ai Therapeutics Inc | Apilimod para utilização no tratamento de melanoma |
| JP6705828B2 (ja) | 2014-11-07 | 2020-06-03 | エイアイ・セラピューティクス・インコーポレーテッド | 腎癌の処置に使用するためのアピリモド |
| US9822190B2 (en) * | 2015-01-29 | 2017-11-21 | Shaker A. Mousa | Compositions and method for anti-sickling of red blood cells in sickle cell disease |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| US11576895B2 (en) | 2016-01-11 | 2023-02-14 | Epicentrx, Inc | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone |
| WO2018031967A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| EP3496756A4 (en) | 2016-08-12 | 2020-07-22 | L.E.A.F Holdings Group LLC | ALPHA AND GAMMA-D ANTIFOLATES OF POLYGLUTAMATES AND THEIR USES. |
| KR20190128619A (ko) | 2016-10-14 | 2019-11-18 | 에피센트알엑스, 인코포레이티드 | 의약에서 사용하기 위한 술폭시알킬 오르가노니트로 및 관련 화합물 및 제약 조성물 |
| US10016425B2 (en) | 2016-11-03 | 2018-07-10 | King Saud University | Anti-ulcerative colitis compound |
| KR102869384B1 (ko) | 2017-07-07 | 2025-10-15 | 에피센트알엑스, 인코포레이티드 | 치료제의 비경구 투여를 위한 조성물 |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| EP3749317A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| CA3090391A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| US12310966B2 (en) | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| WO2019157145A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| JP7487107B2 (ja) | 2018-02-07 | 2024-05-20 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用 |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| WO2019157121A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| CN111954529A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化氨甲蝶呤及其用途 |
| WO2019157148A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| EP3752156A4 (en) | 2018-02-14 | 2021-10-27 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| EP3755335A4 (en) | 2018-02-14 | 2022-06-22 | L.E.A.F Holdings Group LLC | GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES |
| EP3752155A4 (en) | 2018-02-14 | 2022-03-16 | L.E.A.F Holdings Group LLC | GAMMA POLYGLUTAMATE METHOTREXATE AND USES THEREOF |
| WO2019164861A1 (en) | 2018-02-21 | 2019-08-29 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| CN112058287B (zh) * | 2020-08-25 | 2023-04-18 | 浙江工业大学 | 一种二维金属硒化物@MXene复合电催化剂的原位制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5028554A (en) * | 1986-07-03 | 1991-07-02 | Oki Electric Industry Co., Ltd. | Process of fabricating an MIS FET |
| US4818753A (en) * | 1987-09-18 | 1989-04-04 | Sri International | Synthesis and method of use for 2, 4 diaminoquinazoline |
| JP2830008B2 (ja) | 1988-04-01 | 1998-12-02 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体 |
| US4996206A (en) | 1989-12-11 | 1991-02-26 | The Trustees Of Princeton University | N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives |
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| US5248775A (en) | 1989-12-11 | 1993-09-28 | The Trustees Of Princeton University | Pyrrolo(2,3-d)pyrimidines |
| US5073554A (en) | 1990-01-18 | 1991-12-17 | Nair Madhavan G | Two non-polyglutamatable antifolates |
| US4996207A (en) | 1990-01-18 | 1991-02-26 | Nair Madhavan G | Three new non-polyglutamatable deazaaminopterins |
| US5508281A (en) * | 1991-04-08 | 1996-04-16 | Duquesne University Of The Holy Ghost | Derivatives of pyrido [2,3-d] and [3,2-d] pyrimidine and methods of using these derivatives |
| AU3276793A (en) | 1991-12-20 | 1993-07-28 | Agouron Pharmaceuticals, Inc. | Antifolate quinazolines |
| IL108630A0 (en) | 1993-02-18 | 1994-05-30 | Fmc Corp | Insecticidal substituted 2,4-diaminoquinazolines |
| US5550128A (en) | 1994-09-09 | 1996-08-27 | Nair; Madhavan G. | Enantiomers of gamma methylene 10-deaza aminopterin and process for preparing the same |
| US5593999A (en) | 1995-06-07 | 1997-01-14 | Nair; Madhavan G. | Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT) |
| EP1001799B1 (de) * | 1997-07-07 | 2001-10-31 | PTC Pharma AG | Pharmazeutische zusammensetzung enthaltend peptichemio |
| US5912251A (en) * | 1998-01-17 | 1999-06-15 | Nair; Madhavan G. | Metabolically inert anti-inflammatory and anti-tumor antifolates |
| US6048736A (en) * | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| JP4870314B2 (ja) * | 2000-05-02 | 2012-02-08 | セラヴァンス， インコーポレーテッド | シクロデキストリンを含むグリコペプチド抗生物質組成物 |
| PL363962A1 (en) | 2000-11-28 | 2004-11-29 | Genentech, Inc. | Lfa-1 antagonist compounds |
| ATE327223T1 (de) | 2001-04-04 | 2006-06-15 | Bionumerik Pharmaceuticals Inc | Verfahren zur kupplung von aminosäuren an das gerüst eines folsäureantagonisten |
| US20030181635A1 (en) | 2002-03-22 | 2003-09-25 | Harry Kochat | Process for coupling amino acids to an antifolate scaffold |
| US20040092739A1 (en) * | 2002-11-13 | 2004-05-13 | Zejun Xiao | Process for synthesizing antifolates |
| US7060825B2 (en) * | 2003-07-25 | 2006-06-13 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing 6-quinazolinyl-ethyl-benzoyl and related antifolates |
| US7612071B2 (en) * | 2004-03-12 | 2009-11-03 | Syntrix Biosystems, Inc. | Compositions and methods employing aminopterin |
| EP1791544A4 (en) | 2004-09-08 | 2007-09-12 | Chelsea Therapeutics Inc | CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE |
| US7687473B2 (en) | 2005-01-07 | 2010-03-30 | Health Research, Inc. | 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
-
2005
- 2005-09-08 EP EP05806392A patent/EP1791544A4/en active Pending
- 2005-09-08 WO PCT/US2005/032352 patent/WO2006029385A2/en not_active Ceased
- 2005-09-08 JP JP2007531414A patent/JP2008512490A/ja active Pending
- 2005-09-08 AU AU2005282241A patent/AU2005282241B2/en not_active Ceased
- 2005-09-08 US US11/223,433 patent/US7829708B2/en not_active Expired - Fee Related
- 2005-09-08 CA CA2579096A patent/CA2579096C/en not_active Expired - Fee Related
-
2010
- 2010-10-05 US US12/898,291 patent/US20110082149A1/en not_active Abandoned
- 2010-10-05 US US12/898,297 patent/US20110081338A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008512490A5 (OSRAM) | ||
| TWI760331B (zh) | 可溶性C5aR拮抗劑 | |
| US10752598B2 (en) | Aryldiazepine derivatives as RSV inhibitors | |
| ES2881395T3 (es) | Composiciones y métodos para inhibir la actividad de la arginasa | |
| CA2579096A1 (en) | Quinazoline derivatives as metabolically inert antifolate compounds | |
| US12194032B2 (en) | Method of treating focal segmental glomerulosclerosis | |
| EP1948242B1 (en) | Cytotoxic compounds | |
| ES2682043T3 (es) | Ibrutinib deuterado | |
| JP6633092B2 (ja) | チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法 | |
| US10316030B2 (en) | Crystal forms of glutaminase inhibitors | |
| RS58335B1 (sr) | Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena | |
| BR112018010118B1 (pt) | Inibidores de cxcr2 | |
| US20180193352A1 (en) | Heteroaryldiazepine derivatives as rsv inhibitors | |
| JP2009519243A5 (OSRAM) | ||
| US11001581B2 (en) | Compounds which inhibit RNA polymerase, compositions including such compounds, and their use | |
| CN114206338A (zh) | 作为pd-l1抑制剂的二氢化茚类 | |
| JP2010502736A5 (OSRAM) | ||
| CN111344018B (zh) | 聚乙二醇化卡非佐米化合物的稳定的组合物 | |
| JP2004529172A5 (OSRAM) | ||
| US20220193106A1 (en) | Nucleobase analogue derivatives and their applications | |
| CN115916200A (zh) | 炎症性肠病的治疗 | |
| EP4097119B1 (en) | Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases | |
| WO2015153560A1 (en) | Stabilized peptoid-peptide hybrids and uses thereof | |
| JP2010500971A5 (OSRAM) | ||
| JP2007500158A5 (OSRAM) |